Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dust mite mixture** is a Zhejiang Wolwo Bio-Pharmaceutical allergen-specific immunotherapy product developed as a sublingual liquid drop formulation for dust-mite-induced allergic disease. Its active components are allergen proteins from *Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*. The product completed a multicenter, randomized, double-blind, placebo-controlled Phase 2 study in moderate-to-severe perennial allergic rhinitis; Zhejiang Wolwo terminated further development of the program in November 2022 in favor of solid-form dust-mite allergen products. ([static.cninfo.com.cn](https://static.cninfo.com.cn/finalpage/2022-11-29/1215231021.PDF))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dust mite mixture.